AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a ...

Under the terms of the settlement agreement, Axsome will grant Teva a license to sell its generic version of AUVELITY beginning on or after March 31, 2039, if pediatric exclusivity is granted for ...

Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...

Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price boosted by investment analysts at Bank of America ...